Hua Medicine Ltd. (HK:2552)
:2552
Want to see HK:2552 full AI Analyst Report?
2552 Stock Chart & Stats
HK$3.29
-HK$0.05(-3.62%)
At close: 4:00 PM EST
HK$3.29
-HK$0.05(-3.62%)
Day’s Range― - ―
52-Week RangeHK$2.30 - HK$4.95
Previous CloseN/A
Volume1.46M
Average Volume (3M)6.34M
Market Cap
HK$3.17B
Enterprise ValueHK$2.03B
Total Cash (Recent Filing)HK$1.09B
Total Debt (Recent Filing)HK$301.80M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding1,056,605,000
10 Day Avg. Volume6,422,209
30 Day Avg. Volume6,335,350
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.71
Price to Sales (P/S)5.69
P/FCF Ratio-45.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.04
Revenue Forecast (FY)HK$1.04B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Improving Gross MarginRevenue acceleration alongside a materially higher gross margin signals improving product economics and stronger unit profitability. Over 2–6 months this supports operating leverage as sales scale, improves ROI on commercialization, and increases the likelihood of converting top-line gains into durable profits.
Focused Specialty Franchise In Type 2 DiabetesA concentrated franchise in metabolic disease and type 2 diabetes targets a large, chronic market with structural demand. Specialization builds clinical, regulatory and commercial expertise in China, supporting differentiated product positioning, higher retention, and more predictable recurring revenue over the medium term.
Improved Leverage And Equity RecoveryLower leverage and a return to positive equity materially improve the balance-sheet buffer versus 2024. Manageable debt levels and recovered equity increase financial flexibility to fund clinical programs or commercialization, reducing immediate refinance risk and supporting strategic execution durability.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flow despite recent net income undermines internal funding capacity. Poor cash conversion raises reliance on external financing to sustain R&D and commercialization spending, increasing liquidity and execution risk over the coming months.
Persistent Operating LossesDeep negative operating and EBITDA margins show the core business has not reached sustainable profitability despite revenue gains. Continued operating losses limit durable cash generation and require either structural margin improvement or external funding to achieve long-term self-sufficiency.
Volatile Earnings Quality And Equity SwingsNet income strength appears driven by non-operating items while operating performance remains weak; equity also swung markedly across years. This volatility and lower-quality earnings reduce predictability of future profits, complicating cash-flow forecasting and investor confidence over the medium term.
Hua Medicine News
2552 FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was HK$2.30 and its highest was HK$4.95 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is HK$3.17B.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 85 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.085.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of -HK$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.634%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HK:2552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
2552 Company Deck
2552 Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
HUTCHMED (China)
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Options Prices
Currently, No data available
---